BMO Capital Cuts Price Target On HCA Healthcare

BMO Capital has lowered the price target on HCA Healthcare Inc HCA to $250 from $275 while keeping the Market Perform rating on the shares after its Q4 results. 

  • Analyst Matt Borsch notes execution was very strong, but HCA still contends with near-term issues that include uneven volumes, staffing constraints, and related wage and other inflation.
  • The analyst also adds that the Q4 results are likely to continue to be volatile.
  • Related: HCA Healthcare Q4 Earnings Lag Estimates, Issues FY22 Guidance.
  • After the earnings, Cowen lowered the price target from $302 to $265 and kept an Outperform rating on the shares. 
  • The analyst updated his model by slightly lowering its EBITDA for 2022, 2023, and 2024 due to COVID costs/occupancy and deferred surgical recovery labor costs.
  • Price Action: HCA shares are up 1.55% at $240.26 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: NewsHealth CarePrice TargetAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!